Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7861 USD | +3.57% | +4.81% | -58.41% |
Sales 2024 * | 38.74M 52.96M | Sales 2025 * | 50.93M 69.62M | Capitalization | 48.13M 65.79M |
---|---|---|---|---|---|
Net income 2024 * | -87M -119M | Net income 2025 * | -69M -94.32M | EV / Sales 2024 * | 1.24 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.95 x |
P/E ratio 2024 * |
-0.41
x | P/E ratio 2025 * |
-0.62
x | Employees | 344 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
Latest transcript on Bionano Genomics, Inc.
1 day | +3.57% | ||
1 week | +4.81% | ||
Current month | -29.18% | ||
1 month | -24.41% | ||
3 months | -35.57% | ||
6 months | -40.45% | ||
Current year | -58.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Holmlin
CEO | Chief Executive Officer | 56 | 11-01-11 |
Gülsen Kama
DFI | Director of Finance/CFO | 51 | 23-09-10 |
Shroff Hema
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 18-06-30 | |
David Barker
CHM | Chairman | 82 | 10-05-10 |
Albert Luderer
BRD | Director/Board Member | 75 | 11-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 9 M€ | +6.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.7861 | +3.57% | 560,981 |
24-04-25 | 0.759 | -0.28% | 840,708 |
24-04-24 | 0.7611 | -4.19% | 797,490 |
24-04-23 | 0.7944 | +4.44% | 825,832 |
24-04-22 | 0.7606 | +1.41% | 871,068 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.41% | 48.13M | |
+8.07% | 219B | |
+6.59% | 183B | |
+11.26% | 133B | |
+26.57% | 108B | |
+13.35% | 52.02B | |
-0.62% | 48.2B | |
-0.93% | 40.37B | |
+11.54% | 39.35B | |
+26.76% | 32.03B |
- Stock Market
- Equities
- BNGO Stock